Low Temelimab Doses in RRMS Trial Among Reasons for Poor Results

Low Temelimab Doses in RRMS Trial Among Reasons for Poor Results

300075

Low Temelimab Doses in RRMS Trial Among Reasons for Poor Results

Low doses selected and underlying inflammatory disease may have confounded the ability of temelimab to significantly affect neuroinflammation in a Phase 2 trial in relapsing-remitting multiple sclerosis (RRMS) patients. GeNeuro‘s investigational MS therapy did, however, show other evidence of clinical benefit that supports its continued development, researchers reported. Their recently published analysis of that trial explores these issues. That analysis, “Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension…

You must be logged in to read/download the full post.